Financial Performance - The company reported a basic earnings per share of 0.2132 yuan for Q1 2025, representing a 7.24% increase compared to 0.1988 yuan in Q1 2024 [1] - The net profit for Q1 2025 was 0.23 billion yuan, a 4.55% increase from 0.22 billion yuan in Q1 2024 [1] - Operating revenue decreased by 23.97% to 1.11 billion yuan in Q1 2025 from 1.46 billion yuan in Q1 2024 [1] - The return on equity was 1.68% in Q1 2025, slightly up from 1.60% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 34.886 million shares, accounting for 50.67% of the circulating shares, with a decrease of 186,200 shares compared to the previous period [2] - The largest shareholder, Wenze Hong, holds 8.4 million shares, representing 12.20% of the total share capital, with no change [2] - New entrants to the top ten shareholders include Ding Guiying with 299,400 shares (0.43%) and Ding Weifeng with 273,300 shares (0.40%) [2] Dividend Policy - The company has decided not to distribute dividends or allocate shares this time [3]
科源制药:2025一季报净利润0.23亿 同比增长4.55%